- Home
- FRPT vs ELVN Comparison
FRPT vs ELVN Comparison
Compare FRPT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRPT | ELVN |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FRPT | ELVN |
|---|---|---|
| Price | $56.38 | $49.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 5 |
| Target Price | ★ $76.94 | $43.40 |
| AVG Volume (30 Days) | 1.6M | ★ 2.3M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 183.87 | 3.17 |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $1,102,015,000.00 | N/A |
| Revenue This Year | $11.34 | N/A |
| Revenue Next Year | $9.13 | N/A |
| P/E Ratio | $61.96 | ★ N/A |
| Revenue Growth | ★ 13.01 | N/A |
| 52 Week Low | $46.45 | $14.79 |
| 52 Week High | $86.00 | $52.39 |
Technical Indicators
Market Signals| Indicator | FRPT | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 53.79 | 64.02 |
| Support Level | $48.06 | $17.89 |
| Resistance Level | $56.51 | N/A |
| Average True Range (ATR) | 3.32 | 3.35 |
| MACD | 0.61 | 0.60 |
| Stochastic Oscillator | 57.20 | 80.81 |
Price Performance
Historical ComparisonAbout FRPT Freshpet Inc.
Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (likely representing well north of 90% of sales), with cats and treats nascent contributors. Geographically, the company's home US market, where all its food is produced, accounts for nearly all of sales, with exports to Canada, the United Kingdom, and other European countries being very small contributors.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.